Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXS NASDAQ:GERN NASDAQ:MYGN NASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXSCodexis$2.68+1.5%$2.64$1.90▼$6.08$238.76M2.5521,918 shs415,285 shsGERNGeron$1.39+0.7%$1.35$1.09▼$4.50$880.46M0.576.86 million shs7.81 million shsMYGNMyriad Genetics$7.74+1.3%$6.65$3.76▼$25.25$710.86M1.971.48 million shs787,831 shsZBIOZenas BioPharma$27.76+7.2%$18.64$5.83▼$28.72$1.09BN/A317,793 shs832,424 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXSCodexis+3.13%+5.60%+7.76%-15.11%-14.01%GERNGeron+6.98%-2.13%+0.73%0.00%-67.68%MYGNMyriad Genetics+1.46%-1.16%+10.56%+38.91%-70.57%ZBIOZenas BioPharma+24.22%+17.09%+20.41%+114.58%+2,589,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXSCodexis$2.68+1.5%$2.64$1.90▼$6.08$238.76M2.5521,918 shs415,285 shsGERNGeron$1.39+0.7%$1.35$1.09▼$4.50$880.46M0.576.86 million shs7.81 million shsMYGNMyriad Genetics$7.74+1.3%$6.65$3.76▼$25.25$710.86M1.971.48 million shs787,831 shsZBIOZenas BioPharma$27.76+7.2%$18.64$5.83▼$28.72$1.09BN/A317,793 shs832,424 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXSCodexis+3.13%+5.60%+7.76%-15.11%-14.01%GERNGeron+6.98%-2.13%+0.73%0.00%-67.68%MYGNMyriad Genetics+1.46%-1.16%+10.56%+38.91%-70.57%ZBIOZenas BioPharma+24.22%+17.09%+20.41%+114.58%+2,589,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXSCodexis 2.00Hold$11.00310.45% UpsideGERNGeron 2.13Hold$3.79172.35% UpsideMYGNMyriad Genetics 2.13Hold$12.4560.91% UpsideZBIOZenas BioPharma 2.50Moderate Buy$38.3338.09% UpsideCurrent Analyst Ratings BreakdownLatest CDXS, ZBIO, GERN, and MYGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/9/2025ZBIOZenas BioPharmaWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$35.00 ➝ $40.0010/9/2025ZBIOZenas BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.0010/8/2025CDXSCodexisWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025GERNGeronWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ZBIOZenas BioPharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CDXSCodexisWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025GERNGeronWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MYGNMyriad GeneticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ZBIOZenas BioPharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/10/2025GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell$1.00(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXSCodexis$59.35M4.08N/AN/A$0.82 per share3.27GERNGeron$76.99M11.52N/AN/A$0.46 per share3.02MYGNMyriad Genetics$837.60M0.86$1.01 per share7.65$7.70 per share1.01ZBIOZenas BioPharma$5M233.79N/AN/A$7.48 per share3.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXSCodexis-$65.28M-$0.83N/AN/AN/A-113.67%-105.83%-46.06%10/30/2025 (Estimated)GERNGeron-$174.57M-$0.13N/AN/AN/A-53.52%-31.37%-16.01%11/6/2025 (Estimated)MYGNMyriad Genetics-$127.30M-$4.28N/AN/AN/A-47.45%-5.17%-3.44%11/6/2025 (Estimated)ZBIOZenas BioPharma-$156.99M-$3.55N/A∞N/AN/A-59.21%-50.56%11/11/2025 (Estimated)Latest CDXS, ZBIO, GERN, and MYGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025GERNGeron-$0.03N/AN/AN/A$55.24 millionN/A11/6/2025Q3 2025MYGNMyriad Genetics-$0.01N/AN/AN/A$205.26 millionN/A10/30/2025Q3 2025CDXSCodexis-$0.15N/AN/AN/A$18.52 millionN/A8/13/2025Q2 2025CDXSCodexis-$0.17-$0.16+$0.01-$0.16$14.18 million$15.33 million8/12/2025Q2 2025ZBIOZenas BioPharma-$1.02-$1.25-$0.23-$1.25$5.00 millionN/A8/6/2025Q2 2025GERNGeron-$0.03-$0.02+$0.01-$0.02$47.30 million$49.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDXSCodexisN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/AZBIOZenas BioPharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXSCodexis0.715.825.70GERNGeron0.467.876.79MYGNMyriad GeneticsN/A1.421.28ZBIOZenas BioPharmaN/A5.235.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXSCodexis78.54%GERNGeron73.71%MYGNMyriad Genetics99.02%ZBIOZenas BioPharmaN/AInsider OwnershipCompanyInsider OwnershipCDXSCodexis1.90%GERNGeron7.42%MYGNMyriad Genetics2.40%ZBIOZenas BioPharma16.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXSCodexis25090.27 million88.55 millionOptionableGERNGeron70638.02 million590.68 millionOptionableMYGNMyriad Genetics2,70093.04 million90.81 millionOptionableZBIOZenas BioPharmaN/A42.11 million35.16 millionN/ACDXS, ZBIO, GERN, and MYGN HeadlinesRecent News About These CompaniesHC Wainwright & Co. Reiterates Zenas BioPharma (ZBIO) Buy RecommendationOctober 9 at 2:52 PM | msn.comZenas BioPharma rises after Wedbush raises price targetOctober 9 at 2:52 PM | msn.comZenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare DealOctober 9 at 8:19 AM | seekingalpha.comStrategic Expansion and Financial Strength Bolster Zenas BioPharma’s Growth Potential: Buy Rating ReaffirmedOctober 9 at 6:51 AM | tipranks.comZenas BioPharma (Nasdaq:ZBIO) Secures License for Three Autoimmune Candidates Including OrelabrutinibOctober 9 at 4:48 AM | kalkinemedia.comKZenas Biopharma stock soars after securing rights to MS drug candidateOctober 8 at 6:46 PM | za.investing.comZenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase ...October 8 at 6:46 PM | finance.yahoo.comZenas Biopharma Acquires Rights to Three Autoimmune Drug Candidates from InnoCareOctober 8 at 6:46 PM | msn.comZenas climbs on licensing deal with InnoCareOctober 8 at 6:46 PM | msn.comZenas BioPharma (NASDAQ:ZBIO) Receives "Sell (D-)" Rating from Weiss RatingsOctober 8 at 1:06 PM | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Shares Gap Up - What's Next?October 8 at 11:26 AM | marketbeat.comZenas BioPharma Secures Licensing Deal with InnoCareOctober 8 at 6:31 AM | tipranks.comZenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drugOctober 8 at 6:04 AM | reuters.comZenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple SclerosisOctober 8 at 5:00 AM | globenewswire.comZenas BioPharma (NASDAQ:ZBIO) Trading 8.9% Higher - Here's What HappenedOctober 6 at 7:31 PM | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Shares Down 5.3% - What's Next?October 2, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Shares Up 5% - Should You Buy?September 30, 2025 | marketbeat.comBullish Zenas BioPharma Insiders Loaded Up On US$1.11m Of StockSeptember 30, 2025 | finance.yahoo.comGoldman Sachs Group Inc. Cuts Stake in Zenas BioPharma, Inc. $ZBIOSeptember 30, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Cut to Sell at Wall Street ZenSeptember 27, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Trading 7.4% Higher - Should You Buy?September 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDXS, ZBIO, GERN, and MYGN Company DescriptionsCodexis NASDAQ:CDXS$2.68 +0.04 (+1.52%) Closing price 04:00 PM EasternExtended Trading$2.70 +0.02 (+0.75%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Geron NASDAQ:GERN$1.39 +0.01 (+0.72%) Closing price 04:00 PM EasternExtended Trading$1.41 +0.02 (+1.44%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Myriad Genetics NASDAQ:MYGN$7.74 +0.10 (+1.31%) Closing price 04:00 PM EasternExtended Trading$7.71 -0.03 (-0.44%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Zenas BioPharma NASDAQ:ZBIO$27.76 +1.86 (+7.18%) As of 04:00 PM EasternZenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
